Breaking News Instant updates and real-time market news.

MS

Morgan Stanley

$47.97

-0.29 (-0.60%)

, SNAP

Snap

$11.40

-0.35 (-2.98%)

10:13
04/18/19
04/18
10:13
04/18/19
10:13

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MS

Morgan Stanley

$47.97

-0.29 (-0.60%)

SNAP

Snap

$11.40

-0.35 (-2.98%)

WBA

Walgreens Boots Alliance

$54.90

-0.29 (-0.53%)

RAD

Rite Aid

$0.46

-0.0262 (-5.40%)

CF

CF Industries

$44.00

-0.63 (-1.41%)

FMC

FMC Corporation

$80.14

-0.61 (-0.76%)

  • 23

    Apr

  • 30

    Apr

  • 07

    May

  • 08

    May

  • 19

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 11

    Jun

  • 13

    Nov

MS Morgan Stanley
$47.97

-0.29 (-0.60%)

04/16/19
BMOC
04/16/19
NO CHANGE
Target $260
BMOC
Market Perform
Goldman Sachs price target lowered to $260 from $262 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on Goldman Sachs (GS) to $260 and kept his Market Perform rating after its Q1 results. The analyst says that in spite of the company's "broad-based beat", he is lowering his FY20 EPS view to $27.06 from $27.66 due to lower expected Investing and Lending net revenues along with higher credit provisions. Fotheringham prefers Morgan Stanley (MS) to Goldman Sachs since the two trade at a similar two-year-forward rolling earnings multiple, but the wealth management-oriented earnings mix of the former implies a premium that he expects to materialize.
04/18/19
BMOC
04/18/19
NO CHANGE
Target $68
BMOC
Outperform
Morgan Stanley price target raised to $68 from $65 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Morgan Stanley to $68 and kept his Outperform rating after its "broad based" Q1 earnings beat, also raising his FY19 and FY20 EPS view by 22c and $1.11 to $5.16 and $5.95 respectively. The analyst contends that at a 2-year-forward rolling earnings multiple of 7.9-times, the market "fails to appreciate" Morgan Stanley's wealth management-rich business mix, while also pointing to the "pent-up deal pipeline" for the rest of the 2019.
04/18/19
SBSH
04/18/19
DOWNGRADE
Target $48
SBSH
Neutral
Morgan Stanley downgraded to Neutral from Buy at Citi
Citi analyst Keith Horowitz downgraded Morgan Stanley to Neutral from Buy with an unchanged price target of $48. The analyst finds the stock fairly valued following the company's Q1 results.
04/18/19
SBSH
04/18/19
DOWNGRADE
Target $48
SBSH
Neutral
Citi downgrades Morgan Stanley to Neutral despite 'strong' Q1 results
Citi analyst Keith Horowitz downgraded Morgan Stanley to Neutral from Buy with an unchanged price target of $48. The stock in premarket trading is down 45c to $47.81. Morgan reported "strong" Q1 results but the shares are fairly valued, Horowitz tells investors in a research note. The analyst points out the stock has outperformed peers by rallying 22% year-to-date. Though Morgan Stanley has "very high quality" franchises and the potential to continue to gain market share, "we'd rather be on the sidelines in the near-term," says Horowitz.
SNAP Snap
$11.40

-0.35 (-2.98%)

04/18/19
WEDB
04/18/19
DOWNGRADE
Target $12.25
WEDB
Neutral
Snap downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Michael Pachter downgraded Snap to Neutral from Outperform, citing valuation, ahead of the company's Q1 report on April 23. Pachter expects Snap to report Q1 results modestly above guidance and consensus and foresees Q2 guidance roughly in-line with consensus, but he believes the stock's current price leaves little room for upside. He maintains a $12.25 price target on Snap shares.
04/18/19
VERF
04/18/19
DOWNGRADE
VERF
Sell
Snap downgraded to Negative from Mixed at Vertical Group
Vertical Group downgraded Snap to Negative citing slowing spending growth, stagnant ROI, and lower inventory.
04/05/19
RBCM
04/05/19
UPGRADE
RBCM
Outperform
Snap upgraded to Outperform from Sector Perform at RBC Capital
04/05/19
RBCM
04/05/19
UPGRADE
Target $17
RBCM
Outperform
RBC upgrades Snap to Outperform, says 'finally gaining traction' with Android
RBC Capital analyst Mark Mahaney upgraded Snap to Outperform from Sector Perform and raised his price target for the shares to $17 from $10. The stock closed the day up 56c to $11.84. The analyst sees early evidence that its Android platform improvements are "finally gaining traction." Snap may have reached a fundamentals inflection point, Mahaney told investors in a post-close research note. Further, the analyst views the stock's valuation as "much-less demanding" relative to 2017.
WBA Walgreens Boots Alliance
$54.90

-0.29 (-0.53%)

04/17/19
GUGG
04/17/19
DOWNGRADE
Target $59
GUGG
Neutral
Walgreens Boots Alliance assumed with a Neutral from Buy at Guggenheim
04/03/19
04/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank with analyst Chad Dillard saying the biggest risk to the bull case for Caterpillar is if its backlog growth turns negative, "and it is becoming increasingly clear that it will within this next quarter." 2. Dunkin' Brands (DNKN) downgraded to Market Perform from Outperform at BMO Capital with analyst Andrew Strelzik saying that while he remains positive on the company's underlying fundamentals over the long term, he sees risk/reward at current levels as "less persuasive." 3. Tallgrass Energy (TGE) downgraded to Neutral from Buy at Goldman Sachs with analyst Michael Lapides citing the stock's recent outperformance and also warns that its Rockies Express Pipeline natural gas pipeline and Pony Express crude oil pipeline contract roll-offs pose "overhangs," even though the "volume growth out of Bakken, Niobrara, and Powder River Basin could offset this over time." 4. Walgreens Boots Alliance (WBA) downgraded to Hold from Buy at Loop Capital with analyst Andrew Wolf citing the company's disappointing Q2 earnings and FY19 guidance announced yesterday "driven by significantly lower-than-forecasted gross margin resulting from increased pharmacy reimbursement rate pressure in the U.S." 5. Alcoa (AA) downgraded to Neutral from Buy at BofA/Merrill with analyst Timna Tanners saying she now sees limited free cash flow payments by Alcoa to upstream AWAC joint-venture partner Alumina Ltd, potential excess alumina/bauxite supply, and potential price risks from the Alunorte refinery restarting, the world's largest refinery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/19
RHCO
04/03/19
NO CHANGE
Target $58
RHCO
Hold
Walgreens Boots Alliance price target lowered to $58 from $75 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Walgreens Boots Alliance to $58 and kept his Hold rating after its "weak" Q2 results and a "meaningful" cut to its guidance. The analyst says the outlook changes were driven by "reimbursement headwinds, sluggish retail volumes, and a challenging UK operating environment". In spite of the management's "several mitigation efforts", MacDonald contends that industry challenges will not "meaningfully abate in the near/intermediate term", adding that it will take time for Walgreens Boots management to "drive increased efficiency and re-accelerate growth."
04/17/19
GUGG
04/17/19
DOWNGRADE
Target $59
GUGG
Neutral
Walgreens Boots Alliance assumed with a Neutral from Buy at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Walgreens Boots Alliance and downgraded the shares to Neutral from the firm's Buy rating under analyst John Heinbockel. He lowered his price target for the stock to $59 from $75. The analyst is concerned about the continuing structural pressures facing the retail pharmacy industry. Further, the evolution of Walgreens' competitive landscape "will continue to make things difficult for the company," Santangelo tells investors in a research note.
RAD Rite Aid
$0.46

-0.0262 (-5.40%)

04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Rite Aid and downgraded the shares to Sell from the firm's Neutral rating under analyst John Heinbockel. Santangelo also lowered the price target fro Rite Aid to 35c per share, down from 45c per share. The analyst believes Rite Aid's "significant debt burden" and "high leverage will continue to limit Rite Aid's ability to work through its structural and competitive issues."
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
12/20/18
LOOP
12/20/18
NO CHANGE
Target $1
LOOP
Hold
Rite Aid price target lowered to $1.00 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.00 from $1.35 and kept his Hold rating after its Q3 results. The analyst notes that while the company beat on earnings, it brought down the midpoint of its FY19 guidance, which suggests that the company is not yet an an operational inflection point. Wolf adds that while the stock trades at a discount to the drugstore group, he sees it as appropriate given the "higher debt leverage and subscale operations."
CF CF Industries
$44.00

-0.63 (-1.41%)

03/19/19
SBSH
03/19/19
NO CHANGE
SBSH
Citi cuts Q1 fertilizer estimates on slow start to spring season
Citi analyst P.J. Juvekar cut his Q1 earnings for CF Industries (CF), Mosaic (MOS) and Nutrien (NTR) saying the start to the spring has been slow due in part to tough weather conditions in much of the Midwest. The cuts are driven by weather, not a change in fundamentals, Juvekar tells investors in a research note. He expects U.S. demand will pick up soon and thinks it is too early to "throw in the towel" for the spring season. Juvekar prefers shares of Nutrien, CF and Mosaic, in that order, and keeps Buy ratings on all three names.
04/18/19
BOFA
04/18/19
DOWNGRADE
BOFA
Underperform
CF Industries downgraded to Underperform from Buy at BofA/Merrill
03/25/19
COWN
03/25/19
NO CHANGE
COWN
Plantings report likely to create volatility for fertilizer stocks, says Cowen
Cowen analyst Charles Neivert said the annual Prospective Plantings report, due out on Friday, March 29 at noon, is likely to create some volatility around fertilizer shares as it represents the first important data point for the upcoming U.S. agricultural season. Grower economics favor corn over soybean acres as of now, said Neivert, who noted that expectations are for corn and wheat acres to rise, soybean acres to decline, and cotton acres to remain about flat. Agricultural chemicals stocks covered by the firm included CF Industries (CF), Nutrien (NTR), Intrepid Potash (IPI), CVR Partners (UAN) and Mosaic (MOS).
04/18/19
BOFA
04/18/19
DOWNGRADE
Target $38
BOFA
Underperform
CF Industries downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill analyst Steve Byrne downgraded CF Industries to Underperform from Buy and lowered his price target on the shares to $38 from $50. The analyst says he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. Additionally, Byrne notes that the European Commission's recently announced anti-dumping duties on UAN imports from the U.S., Russia, and Trinidad and Tobago could meaningfully cause shipments to reroute from Europe. CF is the largest U.S. exporter of UAN into Europe, which could shift to more U.S. domestic sales, he adds.
FMC FMC Corporation
$80.14

-0.61 (-0.76%)

04/12/19
LOOP
04/12/19
NO CHANGE
Target $102
LOOP
Buy
FMC Corporation earnings forecast reduced at Loop Capital on weather disruptions
Loop Capital analyst Chris Kapsch is lowering his FY19 and FY20 EPS outlook for FMC Corp by 10c to $5.65 and $6.55 respectively, saying a more cautious stance is warranted by the "significant weather-driven disruption in North America" and the possibility of sourcing challenges from China becoming "more acute". In spite of these "transient" challenges, the analyst is keeping his Buy rating and $102 price target on the shares given its "transformational" deal with DuPont to become a "best-in-class Agriculture chemicals franchise", its "well-balanced global portfolio", and the "above-market organic growth prospects."
03/21/19
JEFF
03/21/19
NO CHANGE
Target $112
JEFF
Buy
FMC Corporation added to Top Picks list at Jefferies
Jefferies analyst Laurence Alexander added FMC Corporation to his firm's Top Picks list and boosted his price target for the shares to $112 from $108. FMC's acquisition of key parts of the DuPont crop protection chemical R&D platform has both resolved key structural issues and strengthened FMC's new product pipeline ahead of what will probably be the best half-cycle for crop protection chemicals since the 1990s, Alexander tells investors in a research note. Further, he notes the company is facing easy comparisons off the trough and less pressure from traits than in prior cycles. He sees 30% total return potential over the next year and keeps a Buy rating on FMC Corporation.
04/18/19
RBCM
04/18/19
DOWNGRADE
RBCM
Sector Perform
FMC Corporation downgraded to Sector Perform from Outperform at RBC Capital
04/18/19
04/18/19
DOWNGRADE
Target $87

Sector Perform
FMC Corporation downgraded to Sector Perform at RBC Capital on valuation
As previously reported, RBC Capital analyst Arun Viswanathan downgraded FMC Corp to Sector Perform from Outperform and lowered his price target to $87 from $100 to reflect the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. The analyst states however that the company has an "attractive" pipeline, free cash flow, and capital return plans to justify an above-peer multiple, concluding that the downgrade is also warranted by FMC Corp stock being "closer to fairly valued".

TODAY'S FREE FLY STORIES

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:37
12/07/19
12/07
07:37
12/07/19
07:37
Hot Stocks
PG&E announces $13.5B settlement with victims of California wildfires »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

07:34
12/07/19
12/07
07:34
12/07/19
07:34
Hot Stocks
Amazon leases 335,000 square feet of office space in New York City »

Amazon.com signed a lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.85

5.6 (1.70%)

07:31
12/07/19
12/07
07:31
12/07/19
07:31
Hot Stocks
Tesla CEO Musk cleared in defamation suit over tweet »

A Los Angeles jury on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

ATRC

AtriCure

$30.99

1.29 (4.34%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
AtriCure management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$51.37

0.915 (1.81%)

, AMGN

Amgen

$233.74

0.3 (0.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Clinical Trials on Alzheimer's Disease to hold conference »

12th Clinical Trials on…

ACAD

Acadia

$51.37

0.915 (1.81%)

AMGN

Amgen

$233.74

0.3 (0.13%)

AZN

AstraZeneca

$47.68

0.06 (0.13%)

BIIB

Biogen

$300.27

0.98 (0.33%)

CLB

Core Laboratories

$46.19

1.94 (4.38%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

MRK

Merck

$88.84

0.09 (0.10%)

NVS

Novartis

$92.08

0.42 (0.46%)

RHHBY

Roche

$0.00

(0.00%)

TAK

Takeda Pharmaceutical

$20.27

-0.16 (-0.78%)

VCNX

Vaccinex

$4.95

-0.05 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 16

    Dec

  • 17

    Dec

  • 21

    Jan

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.